REGULATORY DOSSIER- ASEAN COMMON TECHNICAL DOCUMENT (ACTD) FOR ASEM COUNTRIES by J. Neelima, K. Anie Vijetha, A. Srivani, P. Sravanthi
 IAJPS 2017, 4 (12), 4790-4797                       K. Anie Vijetha et al                    ISSN 2349-7750 
 
w w w . i a j p s . c o m  
 
Page 4790 
 
 CODEN [USA]: IAJPBB                        ISSN: 2349-7750 
 
  INDO AMERICAN JOURNAL OF 
  PHARMACEUTICAL SCIENCES 
 
                
 
 
Available online at: http://www.iajps.com                                 Research Article 
 
REGULATORY DOSSIER- ASEAN COMMON TECHNICAL 
DOCUMENT (ACTD) FOR ASEM COUNTRIES 
J. Neelima1, K. Anie Vijetha2, A. Srivani2, P. Sravanthi2  
1Mallareddy Institute of Pharmaceutical Sciences, Hyderabad 
2 Centre for Pharmaceutical Sciences, JNTUH, Hyderabad 
Abstract: 
The Regulatory Affairs department is very often the first point of contact between the government authorities and the 
company. The attitudes and actions of Regulatory Affairs Professionals will condition the perceptions of the 
government officials to the company. Dossier is a collection or file of documents on the same subject, especially a 
file containing detailed information about a person or a topic. Any preparation for human use that is intended to 
modify or explore physiological systems or pathological states for the benefit of the recipient is called as 
“pharmaceutical product for human use”. This guideline merely demonstrates an appropriate write-up format for 
acquired data. Throughout the ACTD, the display of information should be unambiguous and transparent, in order 
to facilitate the review of the basic data and to help a reviewer become quickly oriented to the application contents. 
This ASEAN Common Technical Dossier (ACTD) is a guideline of the agreed upon common format for the 
preparation of a well-structured Common Technical Dossier (CTD) applications that will be submitted to ASEAN 
regulatory authorities for the registration of pharmaceuticals for human use. This guideline describes a CTD format 
that will significantly reduce the time and resources needed to compile applications for registration and in the 
future, will ease the preparation of electronic documental submissions. ICH‐ECTD is an internationally driven 
standard designed to reduce cost in the administration, assessment and archiving of applications for marketing 
authorization of medicinal products for human use, to reduce the use of paper and streamline the assessment 
process making the system more efficient.  
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INTRODUCTION: 
The Regulatory Affairs department is very often the 
first point of contact between the government 
authorities and the company. The attitudes and 
actions of Regulatory Affairs Professionals will 
condition the perceptions of the government officials 
to the company. Dossier is a collection or file of 
documents on the same subject, especially a file 
containing detailed information about a person or a 
topic. Any preparation for human use that is intended 
to modify or explore physiological systems or 
pathological states for the benefit of the recipient is 
called as “pharmaceutical product for human use”. 
Process of reviewing and assessing the dossier of a 
pharmaceutical product containing its detailed data 
(administrative, chemistry, pre-clinical and clinical) 
and the permission granted by the regulatory agencies 
of a country with a view to support its marketing/ or 
approval in a country is called as “Marketing 
Approval” or the “Registration” “Marketing 
Authorization” or the “Product Licensing” [1]. 
 
The goals of dossiers are to provide enough 
information to permit Regulatory Agencies. ICH is a 
joint initiative involving both regulators and research 
based industry representatives          of the European 
Union, Japan and the USA in scientific and technical 
discussions of the testing procedures required to 
assess and ensure the safety, quality and efficacy of 
medicines. The goal of ICH is to promote 
international harmonization by bringing together 
representatives from the three ICH regions (EU, 
Japan and USA) to discuss and establish common 
guidelines [2,3]. 
 
The authorities in the Unites States, European Union 
and Japan ask for the Common Technical Document 
(CTD) format set out by the 2003 International 
Conference on Harmonization (ICH). CTD provide a 
common format for the submission of information to 
the Regulatory Agencies for the registration of the 
pharmaceutical product [4].  
 
The Asia-Europe Meeting (ASEM) [4] was initiated 
in 1996 when the ASEM leaders met in Bangkok, 
Thailand. ASEM is an informal trans- regional 
platform for dialogue and cooperation between the 
two regions and has risen out of a mutual recognition 
that the relationship between Asia and Europe needed 
to be strengthened in light of the challenges and 
opportunities of the 21st century. The Asia-Europe 
Meeting (ASEM) is an informal process of dialogue 
and cooperation bringing together the 27 European 
Union member states, 2 European Countries and the 
European Union with 20 Asian Countries and the  
 
 
ASEAN Secretariat. The initial ASEM partnership in 
1996 consisted of 15 EU member states and 7 
ASEAN member states plus China, Japan, Korea and 
the European Commission. ASEM saw the first 
enlargement during the 5th ASEM summit in 2004 in 
Hanoi (Vietnam), where the 10 EU member states 
(Cyprus, Czech Republic, Estonia, Hungary, Latvia, 
Lithuania, Malta, Poland, Slovakia and Slovenia) and 
three new ASEAN countries (Cambodia, Laos and 
Myanmar) became officially part of the ASEM 
process [2,4].  
 
The second round of enlargement in 2008 during the 
7th summit in Beijing (China) brought in Bulgaria, 
India, Mongolia, Pakistan, Romania and the ASEAN 
secretariat, increasingly total ASEM membership to 
45 partners.  In October 2010, the 8th ASEM summit 
of Heads of Government and State in Brussels 
(Belgium) welcomed three member states to the 
ASEM process: Australia, New Zealand and Russia. 
This third round of enlargement increased total 
ASEM membership to 48 partners. During the 9th 
ASEM summit of Heads of Government and State in 
Vientiane (Laos) in November 2012, ASEM was 
joined officially by Bangladesh, Norway and 
Switzerland. This latest round of enlargement brings 
the total ASEM membership to 51 partners. This 
guideline describes a CTD format that will 
significantly reduce the time and resources needed to 
compile applications for registration and in the 
future. This will ease the preparation of electronic 
documental submissions. Regulatory reviews and 
communication with the applicant will be facilitated 
by a standard document of common elements [4]. 
 
This guideline merely demonstrates an appropriate 
write-up format for acquired data. Throughout the 
ACTD, the display of information should be 
unambiguous and transparent, in order to facilitate 
the review of the basic data and to help a reviewer 
become quickly oriented to the application contents. 
Text and tables should be prepared using margins 
that allow the document to be printed on either A4 or 
8.5 x 11paper. The left hand margin should be 
sufficiently large that information is not obscured by 
the method of binding. Font and size (Times New 
Roman, 12- point font), for text and tables should be 
of a style and size that are large enough to be easily 
legible, even after photocopying. Every page should 
be numbered, with the first page of each part 
designated as page 1. For a paper, Common 
Technical Acronyms and abbreviations should be 
defined the first time they are used in each part. 
References should be cited in accordance with the 
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1979 Vancouver declaration on uniform requirements 
for manuscripts submitted to biomedical journals5. 
The Common Technical Document is organized into 
four parts as follows [6-8]: 
PART 1: Table of contents, administrative data 
and product information: 
Part 1contains initially the overall Table of Contents 
of the whole ACTD to provide basically the 
information’s that could be looked through 
respectively. Secondly, the next content is the 
Administrative Data where required specific 
documentation in details is put together such as 
application forms, label, package insert, etc. the last 
section of this part is Product Information where 
necessary information includes prescribed 
information, mode of action, side effects etc. A 
general introduction to the pharmaceutical, including 
its pharmacologic class and mode of action should be 
included. 
PART II: Quality document: 
Part II should provide the overall summary followed 
by the study reports. The quality control document 
should be described in details as much as possible. 
 
PART III: Nonclinical document: 
Part III should provide the Nonclinical overview, 
followed by the Nonclinical Written Summaries and 
the Nonclinical Tabulated Summaries. The document 
of this part is not required for generic products, minor 
variation products and some major variation 
products. For ASEAN member countries, the study 
reports of this part may not be required for NCE, 
Biotechnological products and other major variation 
products if the original products are already 
registered and approved for market authorization in 
reference countries. Therefore, the authority who 
requires specific study reports should ask for the 
necessary documents. 
PART IV: Clinical document: 
Part IV should provide the clinical overview and the 
clinical summary. The document of this part is not 
required for generic products, minor variation 
products and some major variation products. For 
ASEAN member countries, the study report of this 
part may not be required for NCE, Biotechnological 
products and other major variation products if the 
original products are already registered and approved 
for market authorization in reference countries. 
Therefore, the authority who requires specific study 
reports should ask for necessary documents. 
 
The overall organization of Common Technical Dossier is presented on the following in parts: 
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PART I: Table of content, administrative 
information and prescribing information 
Section A:  Introduction 
Section B:  overall ASEAN Common technical 
dossier Table of Contents 
Section C:  Documents required for registration (for 
example application forms, labeling, Product Data 
Sheet, prescribing information) 
Detailed Overview of part-I 
Administrative information 
Manufacturing information  
Application forms 
Labeling parameters required for Unit carton 
o Product name 
o Dosage form 
o Name of active ingredient (s) 
o Strength of active ingredient(s) 
o Batch number 
o Manufacturing date 
o Expiration date 
o Route of administration 
o Storage condition  
o Country’s registration number 
o Name and address of marketing authorization 
holder 
o Name and address of manufacturer 
o Special labeling (If applicable) e.g. sterile, 
external use, cytotoxic,  alcohol    
o content, animal origin (Bovine, Porcine) 
o Recommended daily allowance (For Vitamins 
and Minerals) 
o Warning (if Applicable) 
o Pack sizes (Unit/Volume) 
Labeling parameters required for inner label 
o Product name 
o Dosage form*  
o Name of active ingredient (s) 
o Strength of active ingredient(s) 
o Batch number 
o Manufacturing date* 
o Expiration date 
o Route of administration 
o Storage condition* 
o Country’s registration number* 
o Name and address of marketing authorization 
holder* 
o Name and address of manufacturer* 
o Special labeling (if Applicable) e.g. sterile, 
external use, cytotoxic, alcohol  
o content, animal origin (Bovine, Porcine)* 
o Recommended daily allowance (For vitamins 
and minerals)* 
o Warning (if Applicable)* 
o Pack sizes (Unit/Volume) 
Labeling parameters required for blisters/strips9 
o Product name 
o Name of active ingredient(s)# 
o Strength of active ingredient(s)# 
o Batch number  
o Expiration date 
o Name/logo of manufacturer/product 
owner/marketing authorization holder   
o (country specific) 
o Country’s registration number (country 
specific) 
Package insert  
           Product name 
o Name and strength of active ingredient(s) 
o Product description 
o Pharmacodynamics/Pharmacokinetics 
o Indication 
o Recommended dose 
o Mode of administration 
o Contraindication 
o Warnings and Precautions 
o Interaction with other medicaments 
o Pregnancy and lactation 
o Undesirable effects 
o Overdose and treatment 
o Storage condition 
o Dosage forms and packaging available 
o Name and address of manufacturer/marketing 
authorization holder 
o Date of revision of package insert 
Summary of product characteristics (Product data 
sheet) 
o Name of the Medicinal Product 
o product Name 
o Strength 
o Pharmaceutical Dosage Form 
o Quality and Quantitative Composition 
o Qualitative Declaration 
o The active substance should be declared by its 
recommended INN           
o Quantitative Declaration 
o The quantity of the active substance must be 
expressed per dosage unit)  
o Pharmaceutical Form 
o Visual description of the appearance of the 
product (colour, markings, etc) e.g.: 
o “Tablet White, circular flat beveled edge 
tablets marked ‘100’ on one side 
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o Clinical Particulars 
o Therapeutic indications 
o Posology and method of administration 
o Contraindications 
o Special warning and precautions for use 
o Interaction with other medicinal products and 
other forms of interactions 
o Pregnancy and lactation 
o Effects on ability to drive and use machine 
o Undesirable effects 
o Overdose 
Pharmacological Properties [10] 
o Pharmacodynamic Properties 
o Pharmacokinetic Properties 
o Preclinical safety Data 
o Pharmaceutical Particulars 
o  List of excipients 
o Incompatibilities 
o Shelf life 
o Shelf life of the medicinal product as packages 
for sale. Shelf life after dilution or    
reconstitution according to directions. Shelf-
life after first opening the container.                                                                                                                                                                                
o Special precautions for storage 
o Nature and contents of container 
o Marketing Authorization Holder 
o  Marketing Authorization Numbers 
o Date of first authorization/renewal of the 
authorization 
o Date of revision of the text 
Patient information leaflet (PIL) 
o Name of Product 
o Description of Product 
o What is in the medicine? 
o Strength of the medicine 
o What is this medicine used for? 
o How much and how often should you use this 
medicine? 
o When should you not take this medicine? 
o Undesirable effects 
o What other medicine or food should be 
avoided whilst taking this medicine? 
o What should you do if you miss a dose? 
o How should you keep this medicine? 
o Signs & Symptoms of over dosage 
o What to do when you have taken more than 
the recommended dosage? 
o Name/logo of 
manufacturer/importer/Marketing 
Authorization Holder 
o Care that should be taken when taking this 
medicine? 
o When should you consult your doctor? 
 
PART II: Quality document  
Section A: Table of contents 
Section B:  Quality overall summary 
Section C:  Body of data  
Detailed overview of part-II 
Table of contents 
A table of contents for the filed application 
should be provided. 
Drug substance 
General information 
o International non–proprietary name (INN) 
o Compendial name if relevant 
o Registry number of chemical abstract service 
(CAS) 
o Laboratory code (if applicable) 
o Chemical name(s) 
o Structural formula 
Pharmaceutical development [11,12] 
o Component of drug product 
o Active ingredients 
o NCE and Biotech: 
The compatibility of the drug substances with 
excipients listed in Item 2.1 should be 
discussed. Additionally, key physicochemical 
characteristics (e.g. Water content, solubility, 
and particle size distribution, polymorphic or 
solid state form) of the drug substance, which 
may influence the performance of the drug 
product should be discussed. 
o Formulation development 
o Overages 
o Physicochemical and biological properties 
Parameters relevant to the performance of the 
drug product such as pH, ionic strength, 
dissolution, redispersion, reconstitution, 
particle size distribution, aggregation, 
polymorphism, rheological properties, 
biological activity or potency and 
immunological activity should be addressed 
[10,11]. 
o Microbiological attributes 
Where appropriate, the microbiological 
attributes of the dosage form should be 
discussed including the rationale for not 
performing microbial limits testing for non-
sterile products, and the selection and 
effectiveness of preservatives systems in 
product containing anti microbial 
preservatives. For sterile products, the 
integrity of the container closure system to 
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prevent microbial contamination should be 
addressed. 
o Compatibility 
The compatibility of the drug product or 
reconstitution diluents(s) or dosage devices, 
e.g. precipitation of drug substance in solution, 
sorption on injection vessels and stability 
should be addressed to provide appropriate and 
supportive information for the labeling. 
o Manufacturing process and process control 
A flow diagram should be presented giving the 
steps of the process and showing where 
materials enter the process. The critical steps 
and points at which process controls, 
intermediate tests or final product controls are 
conducted should be identified. 
o Novel excipients 
For excipient(s) used for the first time in a 
drug product or by a new route of 
administration, details of manufacture, 
characterization and controls, with cross 
references to supporting safety data 
(nonclinical or clinical) should be provided. 
o Control of finished product 
o The specification for the finished product 
should be provided. 
o The analytical procedures use for the testing 
the finished product should be provided. 
o Validation of analytical procedures 
Analytical validation information, including 
experimental data for the analytical procedures 
used for the testing the finished product should 
be provided. 
o Container closure system 
A description of the container closure systems 
should be provided, including the identity of 
materials of construction of each primary and 
secondary packaging component, and each 
specification. The specifications should 
include description and identification (and 
critical dimensions with drawings where 
appropriate). Non-compendial methods (with 
validations) should be included where 
appropriate. 
o Product stability 
Evidence is required to demonstrate that 
product is stable, meets the finished product 
specifications throughout its proposed shelf-
life that toxic decomposition products are not 
produced in significant amount during this 
period, and that potency, efficacy of 
preservative etc. are maintained. 
o Stability data 
o Results of the stability studies should be 
presented in an appropriate format (e.g. 
tabular, graphical, and narrative). Information 
on the analytical procedures used to generate 
the data and 
o validation of these procedures should be 
included. 
PART III: Nonclinical document [13-15] 
Section A: Table of contents 
Section B: Nonclinical overview 
Section C: Nonclinical written and tabulated 
summaries 
1) Table of contents 
2) Pharmacology 
3) Pharmacokinetics 
4) Toxicology 
Section D: Nonclinical study reports 
1) Table of contents 
2) Pharmacology 
3) Pharmacokinetics 
4) Toxicology 
Detailed overview of Part-III 
Table of contents 
Guide on Nonclinical overview and summaries: 
o This guide provides recommendations for the 
harmonization of the Nonclinical Overview, 
Nonclinical Written and Tabulated 
Summaries.  The primary purpose of 
nonclinical written and tabulated summaries 
should be to provide a comprehensive, factual 
synopsis of the nonclinical data. The 
interpretation of the data, the clinical relevance 
of the findings, cross-linking with the quality 
aspects of the pharmaceutical, and the 
implications of the nonclinical findings for the 
safe use of the pharmaceutical (i.e. as 
applicable to labeling) should be addressed in 
the nonclinical overview. 
 
Nonclinical overview 
The nonclinical overview should provide an 
integrated, overall analysis of the information in the 
Common Technical Document. 
 
 Overview of the nonclinical testing strategy 
 Pharmacology 
 Pharmacokinetics 
 Toxicology 
 Integrated overview and conclusions 
 List of literature citations 
  
Order of presentation of information within sections: 
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When available, in vitro studies should precede in 
vivo studies. Where multiple studies of the same type 
are summarized within the Pharmacokinetics and 
Toxicology sections, studies should be ordered by 
species, by route, and then by duration (shortest 
duration first). 
 
Species should be ordered as follows: 
Mouse, Rat, Hamster, Other rodent, Rabbit, Dog, 
Nonhuman primate, other non-rodent mammal, Non 
mammals etc. 
Routes of administration should be ordered as 
follows: 
 
The intended route for human use 
o Oral 
o Intravenous 
o Intramuscular 
o Intraperitoneal 
o Subcutaneous 
o Inhalation 
o Topical 
o Other 
PART IV: Clinical document [13-15] 
Section A: Table of contents 
Section B: Clinical overview 
Section C: Clinical summary 
1) Summary of biopharmaceutics and 
associated analytical methods  
2) Summary of clinical pharmacology studies 
3) Summary of clinical efficacy 
4) Summary of clinical safety 
5) Synopses of individual studies 
Section D: Tabular listing of all clinical studies 
Section E: Clinical study reports 
Section F: List of key literature references 
Detailed overview of part-IV 
Table of contents 
o A table of contents for the filed application 
should be provided. 
Clinical overview 
o The Clinical Overview [13] is intended to 
provide a critical analysis of the clinical data 
in the ASEAN Common Technical Dossier 
(ACTD). 
o Product development rationale 
o Overview of biopharmaceutics 
o The purpose of this section is to present a 
critical analysis of any important issues related 
to bioavailability that might affect efficacy 
and/or safety of the to -be-marketed 
formulation(s) (e.g., dosage form/strength 
proportionality, differences between the to -be-
marketed formulation and the formulation(s) 
used in clinical trials, and influence of food on 
exposure). 
o Overview of Clinical Pharmacology 
o Overview of efficacy 
o Overview of safety 
o Benefits and risks 
o Clinical summary 
 
International conference on harmonization of 
technical requirements for registration of 
pharmaceutical for human use is as per ICH M2 
EWG 
The ICH M4 Expert Working Group (EWG) [14-16] 
has defined the Common Technical Document 
(CTD). The ICH M2 EWG has defined, in the current 
document, the specification for the Electronic 
Common Technical Document (ECTD). The ECTD 
is defined as an interface for industry to agency 
transfer of regulatory information while at the same 
time taking into consideration the facilitation of the 
creation, review, life cycle management and 
archiving of the electronic submission17,18. The 
ECTD specification lists the criteria that will make an 
electronic submission technically valid. The focus of 
the specification is to provide the ability to transfer 
the registration application electronically from 
industry to a regulatory authority. Industry to 
industry and agency to agency transfer is not 
addressed. 
 
The specification for the ECTD is based upon content 
defined within the CTD issued by the ICH M4 EWG. 
The CTD describes the organization of modules, 
sections and documents. The structure and level of 
detail specified in the CTD have been used as the 
basis for defining the ECTD structure and content 
but, where appropriate, additional details have been 
developed within the ECTD specification [19]. 
 
ECTD in the centralized procedure [20] 
In centralized procedure the EMA now only accepts 
submissions received in ECTD format. We 
understand that there may be occasions when 
applicants are unable to comply with this electronic 
requirement and in those circumstances we will 
accept paper submissions. Since January 2013 and 
"Mandatory from March 2014" all ECTD 
submissions must be sent using the dedicated 
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submission channels: eSubmission Gateway or the 
related eSubmission Web Client 
CONCLUSION: 
This ASEAN Common Technical Dossier (ACTD) is 
a guideline of the agreed upon common format for 
the preparation of a well-structured Common 
Technical Dossier (CTD) applications that will be 
submitted to ASEAN regulatory authorities for the 
registration of pharmaceuticals for human use. This 
guideline describes a CTD format that will 
significantly reduce the time and resources needed to 
compile applications for registration and in the 
future, will ease the preparation of electronic 
documental submissions. ICH‐ECTD is an 
internationally driven standard designed to reduce 
cost in the administration, assessment and archiving 
of applications for marketing authorization of 
medicinal products for human use, to reduce the use 
of paper and streamline the assessment process 
making the system more efficient.  
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